Sexual health is an important component of overall health and well being. Multiple factors clearly influence an individual's sexuality; however, there is a general trend in Western societies to blame psychosocial factors for diminished sexuality in women. Sex steroid hormones are important determinants of sexual function in women and men, and there is increasing agreement that androgens play a key role in female sexuality. Androgen levels in women decline substantially during the reproductive years, with little change subsequent to spontaneous menopause. The most common complaint of women experiencing androgen deficiency is loss of sexual desire, and several studies have now shown improvements in a number of parameters of sexuality in postmenopausal women treated with exogenous testosterone.
"Other adverse effects of the use of testosterone in women, such as hirsutism (55), deep voice, and an enlarged clitoris (71), should not be neglected. However, the most common adverse effects are acne and increased oiliness of the skin and hair (55), which were also reported in 3 of the studies shown in Table 1 (26,27,29). "
[Show abstract][Hide abstract] ABSTRACT: With advancing age, there is an increase in the complaints of a lack of a libido in women and erectile dysfunction in men. The efficacy of phosphodiesterase type 5 inhibitors, together with their minimal side effects and ease of administration, revolutionized the treatment of erectile dysfunction. For women, testosterone administration is the principal treatment for hypoactive sexual desire disorder. We sought to evaluate the use of androgens in the treatment of a lack of libido in women, comparing two periods, i.e., before and after the advent of the phosphodiesterase type 5 inhibitors. We also analyzed the risks and benefits of androgen administration. We searched the Latin-American and Caribbean Health Sciences Literature, Cochrane Library, Excerpta Medica, Scientific Electronic Library Online, and Medline (PubMed) databases using the search terms disfunção sexual feminina/female sexual dysfunction, desejo sexual hipoativo/female hypoactive sexual desire disorder, testosterona/testosterone, terapia androgênica em mulheres/androgen therapy in women, and sexualidade/sexuality as well as combinations thereof. We selected articles written in English, Portuguese, or Spanish.
After the advent of phosphodiesterase type 5 inhibitors, there was a significant increase in the number of studies aimed at evaluating the use of testosterone in women with hypoactive sexual desire disorder. However, the risks and benefits of testosterone administration have yet to be clarified.
"Studies examining the effects of exogenous hormone administration to naturally and surgically postmenopausal women support the influence of estrogen therapy on various facets of sexuality, including desire and arousal (Sherwin & Gelfand, 1987; Sherwin, Gelfand, & Brender, 1985). The addition of testosterone improves these dimensions (Davis, 1998; Sherwin & Gelfand, 1987), and testosterone administration also enhances sexual motivation in the absence of estrogen administration (Bancroft , Sanders, Davidson, & Warner, 1983; Sherwin et al., 1985). However, evidence is not entirely consistent. "
[Show abstract][Hide abstract] ABSTRACT: This chapter discusses biological contributions to adolescent female sexual development and, based on a developmental systems framework, suggests future research directions.
New Directions for Child and Adolescent Development 02/2006; 2006(112):9-22. DOI:10.1002/cd.159 · 1.17 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.